PCSK9 siRNA经线粒体途径抑制oxLDL诱导的HUVECs凋亡
|
摘要
研究背景
内膜损伤是动脉粥样硬化(Atherosclerosis, As)的始发环节。研究表明oxLDL引起平滑肌细胞凋亡,可能与上调P53和下调Bcl-2的表达有关。另一些研究已证实oxLDL与细胞膜表面的受体LOX-1结合引起内皮细胞的凋亡,主要经下调Bcl-2的蛋白表达,线粒体依赖性凋亡信号通路。
PCSK9作为一种神经细胞凋亡调节转化酶,参与肝脏的再生,调节神经细胞的凋亡,脂质代谢等多种作用。通过降低肝细胞上LDLR的数量,影响LDL的内化,使血液中LDL不能清除,从而导致高胆固醇血症。高胆固醇血症是一个已被确认的动脉粥样硬化的独立危险因素。另有研究证实PCSK9在胚胎发育中具有促进神经细胞分化的作用,体外细胞实验发现其可参与神经细胞的凋亡,在此过程中有凋亡调节因子Caspase3和死亡受体6的共同调节。本课题组的前期研究表明:PCSK9 siRNA能明显抑制oxLDL诱导的THP-1源性巨噬细胞的凋亡,但其机制不清。PCSK9 siRNA是否对血管内皮细胞的凋亡也有影响还未见报道。
目的
本研究为了检测oxLDL诱导的HUVECs凋亡中PCSK9的表达变化;PCSK9 siRNA是否抑制oxLDL诱导的HUVECs凋亡及探讨其机制。
材料与方法
用不同浓度的oxLDL处理HUVECs 24h,Hoechst33258染色检测细胞凋亡,RT-PCR、western blot分别检测PCSK9 mRNA、LOX-1 mRNA和NARC-1、LOX-1蛋白的表达。应用Lipofectamine2000转染不同浓度的PCSK9 siRNA进入HUVECs,筛选出最有效的siRNA浓度转染HUVECs 24 h后,再加入oxLDL处理24 h,Hoechst33258染色观察评价细胞凋亡,western blot检测凋亡相关蛋白Bcl-2,Bax及Caspase3,-8,-9的表达,酶标法检测Caspase3和Caspase9的活性,Hoechst33258染色观察形态评价细胞凋亡和流式细胞计数凋亡率。
结果
随着oxLDL浓度的不断增加,HUVECs凋亡率逐渐增加,以80μg/ml oxLDL处理24h后,Hoechst33258染色可见大量凋亡细胞。同时RT-PCR、western blot检测发现LOX-1和NARC-1mRNA,蛋白表达均增高。不同浓度的PCSK9 siRNA转染HUVECs后,RT-PCR和western blot筛选出siRNA终浓度,作用细胞24 h后,再用oxLDL处理24 h,Hoechst33258染色和流式细胞术检测oxLDL处理组细胞凋亡率明显增加,转染PCSK9 siRNA组细胞凋亡率明显减少。而RT-PCR和western blot检测结果表明LOX-1的蛋白和mRNA表达在转染PCSK9 siRNA组和oxLDL组无明显差异。Western blot检测结果发现PCSK9 siRNA能明显下调Bax蛋白的表达和上调Bcl-2蛋白的表达,同时观察转染80nmol/L PCSK9 siRNA后用oxLDL处理细胞24小时其对Caspase3,Caspase8和Caspase9的影响,western blot结果显示Caspase3,Caspase9的蛋白表达明显上调,而对Caspase8的蛋白表达无影响。酶标法检测Caspase3,Caspase9的活性均降低。
结论
1.OxLDL能上调PCSK9 mRNA和蛋白质的表达,而PCSK9 siRNA能有效抑制PCSK9基因的表达,从而抑制由oxLDL诱导的HUVECs凋亡。
2.PCSK9 siRNA抑制HUVECs的凋亡主要经Bcl/Bax-Cyt C-Caspase 9-Caspase3线粒体凋亡通路。
Background
Endothelial injury is an initiating factor of atherosclerogenesis. Endothelial cells apoptosis is easier than necrosis leading to the occurrence of atherosclerosis. Studies have shown that smooth muscle cell apoptosis induced by oxLDL may be related to upregulate the expression of P53 and downregulate the expression of Bcl-2. Other studies have confirmed that oxLDL can bind LOX-1 receptor, reduce the expression of Bcl-2 and can inhibit apoptosis induced by a mitochondrial-dependent apoptotic signaling pathway.
PCSK9 as a neural apoptosis-regulated convertase 1, plays an important role in liver regeneration, the differentiation of cortical neurons and lipid metabolism, and other multiple roles by impacts the level of low density lipoprotein receptor (LDLR) in liver.However, excessive accumulation of intracellular LDL affects the clearance of plasma LDL,then resulting in hypercholesterolemia.It has been confirmed that hypercholesterolemia is an independent atherosclerotic risk factor. Scientists have discovered that PCSK9 facilitated the neuronal differentiation in the process of embryonic development, and found to participate in the apoptosis of nerve cells in vitro, apoptotic regulatory factors Caspase3 and co-regulated death receptor 6 may be regulate this process. Our research have showed that PCSK9 siRNA inhibited oxLDL induced THP-1 derived-macrophage apoptosis, but the mechanism is unclear. Whether PCSK9 siRNA also impact apoptosis of endothelial cells have not been reported.
Objective
In order to examine the effect of oxLDL on PCSK9/NARC-1 expression in HUVECs, and examine the role of PCSK9 siRNA on oxLDL induced apoptosis of HUVECs and the expression of apoptotic-related proteins.
Materials and Methods
HUVECs were incubated with diffenrent concentration of oxLDL for 24h.The apoptosis of HUVECs was observed by staining with Hoechst33258; RT-PCR、western blot were conducted to detect the expression of PCSK9、LOX-1 mRNAs and proteins respectively. The PCSK9 siRNAs gene were transfected into HUVECs by positive ion liposome Lipofectamine 2000. Transfection efficiency was assessed by fluorescence microscope assay. The most efficient siRNA was selected to transfected into HUVECs,after transfection for 24 h, cells were treated with oxLDL for 24 h, the rate of HUVECs apoptosis transfected siRNA was detected by staining with Hoechst 33258 and flow cytometer. Western blot was conducted to detect the expression of apototic proteins Bcl-2,Bax,Caspase3,8,9 expressions. The activity of Caspase3,9 was detected by Enzyme linked immunosorbent assay.
Results
The results showed that a number of cells with nuclear condensation induced by 80μg/ml oxLDL for 24h increased significantly,Hoechst33258 staining showed a number of cells apoptosis. PCSK9 was upregulated with increasing concentration of oxLDL in HUVECs, while 80μg/ml oxLDL increased significantly. Moreover,RT-PCR、western blot showed that LOX-1,PCSK9 mRNAs and proteins both increased.The different concentration of PCSK9 siRNAs were transfected into HUVECs,the most effective dose of siRNA was selected by RT-PCR and western blot.HUVECs pretreated with PCSK9 siRNA for 24h , then cells treated with oxLDL for 24h, oxLDL-induced apoptosis was significantly reduced in HUVECs transfected with siRNA detected by staining with Hoechst33258 and flow cytometer. PCSK9 siRNA upregulated Bcl-2 protein expression while Bax expression was decreased. Compared with control,PCSK9 siRNA supressed Caspase3,9 proteins expression,but had on effect on Caspase8. Moreover,activity of Caspase 3,9 both decreased by PCSK9 siRNA.Apopotosis of HUVECs decreased significantly by PCSK9 siRNA,but the expression of LOX-1 between siRNA and oxLDL treatment had no difference.
Conclusions
1.These results revealed that the expression of PCSK9 mRNA and protein were increased by oxLDL. PCSK9 gene expression could be effectively suppressed by siRNA. So oxLDL induced apoptosis of HUVECs could be effectively suppressed by PCSK9 siRNA.
2.Our study demostrated that PCSK9 siRNA inhibits HUVECs apoptosis via Bcl/Bax-Cyt C-Caspase 9-Caspase3 mitochondrial pathway.
内膜损伤是动脉粥样硬化(Atherosclerosis, As)的始发环节。研究表明oxLDL引起平滑肌细胞凋亡,可能与上调P53和下调Bcl-2的表达有关。另一些研究已证实oxLDL与细胞膜表面的受体LOX-1结合引起内皮细胞的凋亡,主要经下调Bcl-2的蛋白表达,线粒体依赖性凋亡信号通路。
PCSK9作为一种神经细胞凋亡调节转化酶,参与肝脏的再生,调节神经细胞的凋亡,脂质代谢等多种作用。通过降低肝细胞上LDLR的数量,影响LDL的内化,使血液中LDL不能清除,从而导致高胆固醇血症。高胆固醇血症是一个已被确认的动脉粥样硬化的独立危险因素。另有研究证实PCSK9在胚胎发育中具有促进神经细胞分化的作用,体外细胞实验发现其可参与神经细胞的凋亡,在此过程中有凋亡调节因子Caspase3和死亡受体6的共同调节。本课题组的前期研究表明:PCSK9 siRNA能明显抑制oxLDL诱导的THP-1源性巨噬细胞的凋亡,但其机制不清。PCSK9 siRNA是否对血管内皮细胞的凋亡也有影响还未见报道。
目的
本研究为了检测oxLDL诱导的HUVECs凋亡中PCSK9的表达变化;PCSK9 siRNA是否抑制oxLDL诱导的HUVECs凋亡及探讨其机制。
材料与方法
用不同浓度的oxLDL处理HUVECs 24h,Hoechst33258染色检测细胞凋亡,RT-PCR、western blot分别检测PCSK9 mRNA、LOX-1 mRNA和NARC-1、LOX-1蛋白的表达。应用Lipofectamine2000转染不同浓度的PCSK9 siRNA进入HUVECs,筛选出最有效的siRNA浓度转染HUVECs 24 h后,再加入oxLDL处理24 h,Hoechst33258染色观察评价细胞凋亡,western blot检测凋亡相关蛋白Bcl-2,Bax及Caspase3,-8,-9的表达,酶标法检测Caspase3和Caspase9的活性,Hoechst33258染色观察形态评价细胞凋亡和流式细胞计数凋亡率。
结果
随着oxLDL浓度的不断增加,HUVECs凋亡率逐渐增加,以80μg/ml oxLDL处理24h后,Hoechst33258染色可见大量凋亡细胞。同时RT-PCR、western blot检测发现LOX-1和NARC-1mRNA,蛋白表达均增高。不同浓度的PCSK9 siRNA转染HUVECs后,RT-PCR和western blot筛选出siRNA终浓度,作用细胞24 h后,再用oxLDL处理24 h,Hoechst33258染色和流式细胞术检测oxLDL处理组细胞凋亡率明显增加,转染PCSK9 siRNA组细胞凋亡率明显减少。而RT-PCR和western blot检测结果表明LOX-1的蛋白和mRNA表达在转染PCSK9 siRNA组和oxLDL组无明显差异。Western blot检测结果发现PCSK9 siRNA能明显下调Bax蛋白的表达和上调Bcl-2蛋白的表达,同时观察转染80nmol/L PCSK9 siRNA后用oxLDL处理细胞24小时其对Caspase3,Caspase8和Caspase9的影响,western blot结果显示Caspase3,Caspase9的蛋白表达明显上调,而对Caspase8的蛋白表达无影响。酶标法检测Caspase3,Caspase9的活性均降低。
结论
1.OxLDL能上调PCSK9 mRNA和蛋白质的表达,而PCSK9 siRNA能有效抑制PCSK9基因的表达,从而抑制由oxLDL诱导的HUVECs凋亡。
2.PCSK9 siRNA抑制HUVECs的凋亡主要经Bcl/Bax-Cyt C-Caspase 9-Caspase3线粒体凋亡通路。
Background
Endothelial injury is an initiating factor of atherosclerogenesis. Endothelial cells apoptosis is easier than necrosis leading to the occurrence of atherosclerosis. Studies have shown that smooth muscle cell apoptosis induced by oxLDL may be related to upregulate the expression of P53 and downregulate the expression of Bcl-2. Other studies have confirmed that oxLDL can bind LOX-1 receptor, reduce the expression of Bcl-2 and can inhibit apoptosis induced by a mitochondrial-dependent apoptotic signaling pathway.
PCSK9 as a neural apoptosis-regulated convertase 1, plays an important role in liver regeneration, the differentiation of cortical neurons and lipid metabolism, and other multiple roles by impacts the level of low density lipoprotein receptor (LDLR) in liver.However, excessive accumulation of intracellular LDL affects the clearance of plasma LDL,then resulting in hypercholesterolemia.It has been confirmed that hypercholesterolemia is an independent atherosclerotic risk factor. Scientists have discovered that PCSK9 facilitated the neuronal differentiation in the process of embryonic development, and found to participate in the apoptosis of nerve cells in vitro, apoptotic regulatory factors Caspase3 and co-regulated death receptor 6 may be regulate this process. Our research have showed that PCSK9 siRNA inhibited oxLDL induced THP-1 derived-macrophage apoptosis, but the mechanism is unclear. Whether PCSK9 siRNA also impact apoptosis of endothelial cells have not been reported.
Objective
In order to examine the effect of oxLDL on PCSK9/NARC-1 expression in HUVECs, and examine the role of PCSK9 siRNA on oxLDL induced apoptosis of HUVECs and the expression of apoptotic-related proteins.
Materials and Methods
HUVECs were incubated with diffenrent concentration of oxLDL for 24h.The apoptosis of HUVECs was observed by staining with Hoechst33258; RT-PCR、western blot were conducted to detect the expression of PCSK9、LOX-1 mRNAs and proteins respectively. The PCSK9 siRNAs gene were transfected into HUVECs by positive ion liposome Lipofectamine 2000. Transfection efficiency was assessed by fluorescence microscope assay. The most efficient siRNA was selected to transfected into HUVECs,after transfection for 24 h, cells were treated with oxLDL for 24 h, the rate of HUVECs apoptosis transfected siRNA was detected by staining with Hoechst 33258 and flow cytometer. Western blot was conducted to detect the expression of apototic proteins Bcl-2,Bax,Caspase3,8,9 expressions. The activity of Caspase3,9 was detected by Enzyme linked immunosorbent assay.
Results
The results showed that a number of cells with nuclear condensation induced by 80μg/ml oxLDL for 24h increased significantly,Hoechst33258 staining showed a number of cells apoptosis. PCSK9 was upregulated with increasing concentration of oxLDL in HUVECs, while 80μg/ml oxLDL increased significantly. Moreover,RT-PCR、western blot showed that LOX-1,PCSK9 mRNAs and proteins both increased.The different concentration of PCSK9 siRNAs were transfected into HUVECs,the most effective dose of siRNA was selected by RT-PCR and western blot.HUVECs pretreated with PCSK9 siRNA for 24h , then cells treated with oxLDL for 24h, oxLDL-induced apoptosis was significantly reduced in HUVECs transfected with siRNA detected by staining with Hoechst33258 and flow cytometer. PCSK9 siRNA upregulated Bcl-2 protein expression while Bax expression was decreased. Compared with control,PCSK9 siRNA supressed Caspase3,9 proteins expression,but had on effect on Caspase8. Moreover,activity of Caspase 3,9 both decreased by PCSK9 siRNA.Apopotosis of HUVECs decreased significantly by PCSK9 siRNA,but the expression of LOX-1 between siRNA and oxLDL treatment had no difference.
Conclusions
1.These results revealed that the expression of PCSK9 mRNA and protein were increased by oxLDL. PCSK9 gene expression could be effectively suppressed by siRNA. So oxLDL induced apoptosis of HUVECs could be effectively suppressed by PCSK9 siRNA.
2.Our study demostrated that PCSK9 siRNA inhibits HUVECs apoptosis via Bcl/Bax-Cyt C-Caspase 9-Caspase3 mitochondrial pathway.
引文
[1] Seidah n g. Benjannet s, Wickham l, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1(NARC-1):liver regeneration and neuronal differentiation[J].Proc Natl Acad Sci USA, 2003,100(3):928-933.
[2] Dimmeler S , Zeiher AM. Endothelial cell apoptosis in angiogenesis and vessel regression[J]. Circulation Research ,2000,87(6): 434-439.
[3] Ermak N, Lacour B, Drüeke TB, et al.Role of reactive oxygen species and Bax in oxidized low density lipoprotein-induced apoptosis of human monocytes[J]. Atherosclerosis, 2008,200(2):247-256.
[4] Yla-Herttuala S, Palinski W, Butler SW, et al. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL[J]. Arterioscler Thromb, 1994, 14(1):32-40.
[5] Mehta JL, Chen J, Hermonat PL, et al. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders[J]. Cardiovasc Res, 2006,69(1): 36-45.
[6] Seidah NG, Mayer G, Zaid A, et al. The activation and physiological functions of the proprotein convertases[J]. Int J Biochem Cell Biol, 2008,40(6–7):1111–1125.
[7] Kume N.Molecular mechanisms of coronary atherosclerotic plaque formation and rupture[J]. Nippon Rinsho, 2010 ,68(4):637-641.
[8] Masahiro S, Keiko T, Naoki M. Effects of soluble TNF-alpha receptor 1 on apoptosis induced by oxidized LDL in endothelial cells[J]. Molecular and Cellular Biochemistry,2004,258(1-2):57-63.
[9] Holvoet P, Jenny NS, Schreiner PJ, et al.The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA) [J]. Atherosclerosis, 2007 ,194(1):245-252.
[10] Yasunobu Y, Hayashi K, Shingu T, et al. Coronary atherosclerosis and oxidative stress as reflected by autoantibodies against oxidized low-density lipoprotein and oxysterols[J]. Atherosclerosis,2001,155(2):445-453.
[11] Hedrick JA.Targeting PCSK9 for the treatment of hypercholesterolemia[J]. CurrOpin Investig Drugs, 2009,10(9):938-946.
[12] Chen SN, Ballantyne CM, Gotto AM, et al. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis[J]. J Am Coll Cardiol,2005,45(10):1611–1619.
[13] Abboud S, Karhunen PJ, Lütjohann D, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke[J]. PLoS One,2007, 2(10):e1043.
[14] Cohen JC, Boerwinkle E, Mosley TH, et al.Sequence variations in PCSK9, low LDL, and protection against coronary heart disease[J]. N Engl J Med,2006,354(12):1264–1272.
[15]程艳丽,谢闵,刘录山等.PCSK9基因突变与胆固醇血症.中国生物化学与分子生物学报(CHENG Yan-Li,XIE Min,LIU Lu-Shan,et al. PCSK9 Gene Mutation and Cholesterolemia[J]. Chinese Journal of Biochemistry and Molecular Biology), 2007, 23 (3):172-176.
[16] Brown MS, Goldstein JL. Biomedicine. Lowing LDL-not only how low, but how long[J]? Science, 2006, 311(5768):1721-1723.
[17] Huang CC, Fornage M, Lloyd-Jones DM, et al.Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study[J]. Circ Cardiovasc Genet, 2009 ,2(4):354-361.
[18] Lan H, Pang L, Smith MM, et,al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells[J]. J Cell Physiol, 2010 Mar 23.
[19] Naoumova RP, Tosi I, Patel D, et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response[J]. Arterioscler Thromb Vasc Biol,2005,25(12): 2654-2660.
[20] Li D, Williams V, Liu L, et al.Expression of lectin-like oxidized low-density lipoprotein receptors during ischemia-reperfusion and its role in determination of apoptosis and left ventricular dysfunction[J]. J Am CollCardiol,2003,41(6):1048–1055.
[21] Chen J, Mehta JL, Haider N, et al.Role of Caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells[J]. Circ Res,2004,94(3):269-270.
[22] Huber J, Vales A, Mitulovic G, et al. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions[J]. Arterioscler Thromb Vasc Biol,2002,22(1):101-107.
[23] Henning Morawietz. LOX-1 and Atherosclerosis: Proof of Concept in LOX-1–Knockout Mice[J].Circ Res,2007,100(11):1534-1536.
[24] Bingham B, Shen R, Kotnis S, et al.Proapoptotic Effects of NARC 1(= PCSK9), the Gene Encoding a Novel Serine Proteinase[J]. Cytometry A, 2006,69(11):1123-1131.
[25] Liu LS,Xie M,Jiang ZS, et al.Effects of PCSK9 siRNA on THP-1 Derived Macrophages Apoptosis Induced by oxLDL[J].Progress in Biochemistry and Biophysics,2009,36(3):323-330.
[26] Kataoka H, Kume N, Miyamoto S, et al. Oxidized LDL modulates Bax/Bcl-2 throμgh the lectin-like Ox-LDL receptor-1 in vascular smooth muscle cells[J]. Arterioscler Thromb Vasc Biol, 2001,21(6):955-960.
[27] Poirier S, Mayer G, Poupon V, et al.Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route[J]. J Biol Chem, 2009,284(42):28856-28864.
[28] Morawietz H.LOX-1 receptor as a novel target in endothelial dysfunction and atherosclerosis[J].Dtsch Med Wochenschr, 2010 ,135(7):308-312.
[29] Dimmeler S, Haendeler J, Galle J, et al. Oxidized low desity lipoprotein induces apoptosis of human endothelial cell by activation of CPP32 like protease:a mechanistic clue to the response to injury hypothesis[J]. Circulation, 1997, 95(7): 1760-1763.
[30] Chen TG, Chen TL, Chang HC, et al. Oxidized low-density lipoprotein induces apoptotic insults to mouse cerebral endothelial cells via aBax–mitochondria–Caspase protease pathway[J]. Toxicol Appl Pharmacol, 2007,219(1):42-53.
[31] Cheng J, Cui R, Chen CH, et al. Oxidized low-density lipoprotein stimulates p53-dependent activation of proapoptotic Bax leading to apoptosis of differentiated endothelial progenitor cells[J]. Endocrinology,2007,148(5):2085-2094.
[1] Robles-Osorio L, Huerta-Zepeda A, Ordó?ez ML, et al.Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico[J].Arch Med Res,2006,37(1):102-108.
[2] Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism[J]. J Lipid Res, 2009,50 Suppl:S172-177.
[3] Graham MJ, Lemonidis KM, Whipple CP, et al.Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice[J].J Lipid Res,2007,48(4):763-767.
[4] Christopher J. Duff, Martin J. Scott, Ian T. Kirby, et al.Antibody-mediated disruption of the interaction between PCSK9 and the lowdensity lipoproteinreceptor[J]. Biochem J,2009,419(3):577-584.
[5] Attie AD.The Mystery of PCSK9[J]. Arterioscler Thromb Vasc Biol, 2004,24(8):1337-1339.
[6] ELINA IKONEN. Mechanisms for Cellular Cholesterol Transport:Defects and Human Disease[J]. Physiol Rev, 2006,86(4):1237-1261.
[7] Cameron J, Holla ?L, Ranheim T,et al.Effect of mutations in the PCSK9 gene on the cell surface LDL receptors[J]. Hum Mol Genet,2006,15(9):1551-1558.
[8] Li J, Tumanut C, Gavigan JA, et al.Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity[J].Biochem J, 2007,406(2):203-207.
[9] Basak A.Inhibitors of proprotein convertases[J]. J Mol Med, 2005,83(11):844-855.
[10]程艳丽,谢闵,刘录山等.PCSK9基因突变与胆固醇血症.中国生物化学与分子生物学报(CHENG Yan-Li,XIE Min,LIU Lu-Shan,et al. PCSK9 Gene Mutation and Cholesterolemia[J]. Chinese Journal of Biochemistry and Molecular Biology), 2007, 23 (3):172-176.
[11] KONGW,WEI J,AB IDI P1.Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins[J].NatMed, 2004,10(12):13442-13511.
[12] Mandel'shtam MIu, Vasil'ev VB.Monogenic hypercholesterolemias: new genes, new drug targets[J].Genetika, 2008,44(10):1309-1316.
[13] Kong WJ, Wei J, Zuo ZY, et al.Combination of simvastatin with berberine improves the lipid-lowering efficacy[J]. Metabolism, 2008,57(8):1029-1037.
[14] Gouni-Berthold I, Berthold HK, Gylling H, et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men[J]. Atherosclerosis, 2008,198(1):198-207.
[15] Kourimate S, Le May C, Langhi C, et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9[J]. J Biol Chem, 2008,283(15):9666-9673.
[16] Langhi C, Le May C, Kourimate S, et al.Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes[J]. FEBS Lett, 2008,582(6):949-955.
[17] Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates[J].Proc Natl Acad Sci U S A, 2008,105(33):11915-11920.
[18]刘录山,谢闵,姜志胜,等.PCSK9 siRNA对oxLDL诱导的THP-1源性巨噬细胞凋亡的影响.生物化学与生物物理进展(LIU Lu-Shan,XIE Min,JIANG Zhi-Sheng, et al.Effects of PCSK9 siRNA on THP-1 Derived Macrophages Apoptosis Induced by oxLDL[J].Progress in Biochemistry and Biophysics,2009, 36(3):323-330.
[19] Mayer G, Poirier S, Seidah NG. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels[J]. J Biol Chem, 2008,283(46): 13791-13801.
[20] Seidah NG. PCSK9 as a therapeutic target of dyslipidemia[J]. Expert Opin Ther Targets, 2009,13(1):19-28.
[2] Dimmeler S , Zeiher AM. Endothelial cell apoptosis in angiogenesis and vessel regression[J]. Circulation Research ,2000,87(6): 434-439.
[3] Ermak N, Lacour B, Drüeke TB, et al.Role of reactive oxygen species and Bax in oxidized low density lipoprotein-induced apoptosis of human monocytes[J]. Atherosclerosis, 2008,200(2):247-256.
[4] Yla-Herttuala S, Palinski W, Butler SW, et al. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL[J]. Arterioscler Thromb, 1994, 14(1):32-40.
[5] Mehta JL, Chen J, Hermonat PL, et al. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders[J]. Cardiovasc Res, 2006,69(1): 36-45.
[6] Seidah NG, Mayer G, Zaid A, et al. The activation and physiological functions of the proprotein convertases[J]. Int J Biochem Cell Biol, 2008,40(6–7):1111–1125.
[7] Kume N.Molecular mechanisms of coronary atherosclerotic plaque formation and rupture[J]. Nippon Rinsho, 2010 ,68(4):637-641.
[8] Masahiro S, Keiko T, Naoki M. Effects of soluble TNF-alpha receptor 1 on apoptosis induced by oxidized LDL in endothelial cells[J]. Molecular and Cellular Biochemistry,2004,258(1-2):57-63.
[9] Holvoet P, Jenny NS, Schreiner PJ, et al.The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA) [J]. Atherosclerosis, 2007 ,194(1):245-252.
[10] Yasunobu Y, Hayashi K, Shingu T, et al. Coronary atherosclerosis and oxidative stress as reflected by autoantibodies against oxidized low-density lipoprotein and oxysterols[J]. Atherosclerosis,2001,155(2):445-453.
[11] Hedrick JA.Targeting PCSK9 for the treatment of hypercholesterolemia[J]. CurrOpin Investig Drugs, 2009,10(9):938-946.
[12] Chen SN, Ballantyne CM, Gotto AM, et al. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis[J]. J Am Coll Cardiol,2005,45(10):1611–1619.
[13] Abboud S, Karhunen PJ, Lütjohann D, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke[J]. PLoS One,2007, 2(10):e1043.
[14] Cohen JC, Boerwinkle E, Mosley TH, et al.Sequence variations in PCSK9, low LDL, and protection against coronary heart disease[J]. N Engl J Med,2006,354(12):1264–1272.
[15]程艳丽,谢闵,刘录山等.PCSK9基因突变与胆固醇血症.中国生物化学与分子生物学报(CHENG Yan-Li,XIE Min,LIU Lu-Shan,et al. PCSK9 Gene Mutation and Cholesterolemia[J]. Chinese Journal of Biochemistry and Molecular Biology), 2007, 23 (3):172-176.
[16] Brown MS, Goldstein JL. Biomedicine. Lowing LDL-not only how low, but how long[J]? Science, 2006, 311(5768):1721-1723.
[17] Huang CC, Fornage M, Lloyd-Jones DM, et al.Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study[J]. Circ Cardiovasc Genet, 2009 ,2(4):354-361.
[18] Lan H, Pang L, Smith MM, et,al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells[J]. J Cell Physiol, 2010 Mar 23.
[19] Naoumova RP, Tosi I, Patel D, et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response[J]. Arterioscler Thromb Vasc Biol,2005,25(12): 2654-2660.
[20] Li D, Williams V, Liu L, et al.Expression of lectin-like oxidized low-density lipoprotein receptors during ischemia-reperfusion and its role in determination of apoptosis and left ventricular dysfunction[J]. J Am CollCardiol,2003,41(6):1048–1055.
[21] Chen J, Mehta JL, Haider N, et al.Role of Caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells[J]. Circ Res,2004,94(3):269-270.
[22] Huber J, Vales A, Mitulovic G, et al. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions[J]. Arterioscler Thromb Vasc Biol,2002,22(1):101-107.
[23] Henning Morawietz. LOX-1 and Atherosclerosis: Proof of Concept in LOX-1–Knockout Mice[J].Circ Res,2007,100(11):1534-1536.
[24] Bingham B, Shen R, Kotnis S, et al.Proapoptotic Effects of NARC 1(= PCSK9), the Gene Encoding a Novel Serine Proteinase[J]. Cytometry A, 2006,69(11):1123-1131.
[25] Liu LS,Xie M,Jiang ZS, et al.Effects of PCSK9 siRNA on THP-1 Derived Macrophages Apoptosis Induced by oxLDL[J].Progress in Biochemistry and Biophysics,2009,36(3):323-330.
[26] Kataoka H, Kume N, Miyamoto S, et al. Oxidized LDL modulates Bax/Bcl-2 throμgh the lectin-like Ox-LDL receptor-1 in vascular smooth muscle cells[J]. Arterioscler Thromb Vasc Biol, 2001,21(6):955-960.
[27] Poirier S, Mayer G, Poupon V, et al.Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route[J]. J Biol Chem, 2009,284(42):28856-28864.
[28] Morawietz H.LOX-1 receptor as a novel target in endothelial dysfunction and atherosclerosis[J].Dtsch Med Wochenschr, 2010 ,135(7):308-312.
[29] Dimmeler S, Haendeler J, Galle J, et al. Oxidized low desity lipoprotein induces apoptosis of human endothelial cell by activation of CPP32 like protease:a mechanistic clue to the response to injury hypothesis[J]. Circulation, 1997, 95(7): 1760-1763.
[30] Chen TG, Chen TL, Chang HC, et al. Oxidized low-density lipoprotein induces apoptotic insults to mouse cerebral endothelial cells via aBax–mitochondria–Caspase protease pathway[J]. Toxicol Appl Pharmacol, 2007,219(1):42-53.
[31] Cheng J, Cui R, Chen CH, et al. Oxidized low-density lipoprotein stimulates p53-dependent activation of proapoptotic Bax leading to apoptosis of differentiated endothelial progenitor cells[J]. Endocrinology,2007,148(5):2085-2094.
[1] Robles-Osorio L, Huerta-Zepeda A, Ordó?ez ML, et al.Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico[J].Arch Med Res,2006,37(1):102-108.
[2] Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism[J]. J Lipid Res, 2009,50 Suppl:S172-177.
[3] Graham MJ, Lemonidis KM, Whipple CP, et al.Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice[J].J Lipid Res,2007,48(4):763-767.
[4] Christopher J. Duff, Martin J. Scott, Ian T. Kirby, et al.Antibody-mediated disruption of the interaction between PCSK9 and the lowdensity lipoproteinreceptor[J]. Biochem J,2009,419(3):577-584.
[5] Attie AD.The Mystery of PCSK9[J]. Arterioscler Thromb Vasc Biol, 2004,24(8):1337-1339.
[6] ELINA IKONEN. Mechanisms for Cellular Cholesterol Transport:Defects and Human Disease[J]. Physiol Rev, 2006,86(4):1237-1261.
[7] Cameron J, Holla ?L, Ranheim T,et al.Effect of mutations in the PCSK9 gene on the cell surface LDL receptors[J]. Hum Mol Genet,2006,15(9):1551-1558.
[8] Li J, Tumanut C, Gavigan JA, et al.Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity[J].Biochem J, 2007,406(2):203-207.
[9] Basak A.Inhibitors of proprotein convertases[J]. J Mol Med, 2005,83(11):844-855.
[10]程艳丽,谢闵,刘录山等.PCSK9基因突变与胆固醇血症.中国生物化学与分子生物学报(CHENG Yan-Li,XIE Min,LIU Lu-Shan,et al. PCSK9 Gene Mutation and Cholesterolemia[J]. Chinese Journal of Biochemistry and Molecular Biology), 2007, 23 (3):172-176.
[11] KONGW,WEI J,AB IDI P1.Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins[J].NatMed, 2004,10(12):13442-13511.
[12] Mandel'shtam MIu, Vasil'ev VB.Monogenic hypercholesterolemias: new genes, new drug targets[J].Genetika, 2008,44(10):1309-1316.
[13] Kong WJ, Wei J, Zuo ZY, et al.Combination of simvastatin with berberine improves the lipid-lowering efficacy[J]. Metabolism, 2008,57(8):1029-1037.
[14] Gouni-Berthold I, Berthold HK, Gylling H, et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men[J]. Atherosclerosis, 2008,198(1):198-207.
[15] Kourimate S, Le May C, Langhi C, et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9[J]. J Biol Chem, 2008,283(15):9666-9673.
[16] Langhi C, Le May C, Kourimate S, et al.Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes[J]. FEBS Lett, 2008,582(6):949-955.
[17] Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates[J].Proc Natl Acad Sci U S A, 2008,105(33):11915-11920.
[18]刘录山,谢闵,姜志胜,等.PCSK9 siRNA对oxLDL诱导的THP-1源性巨噬细胞凋亡的影响.生物化学与生物物理进展(LIU Lu-Shan,XIE Min,JIANG Zhi-Sheng, et al.Effects of PCSK9 siRNA on THP-1 Derived Macrophages Apoptosis Induced by oxLDL[J].Progress in Biochemistry and Biophysics,2009, 36(3):323-330.
[19] Mayer G, Poirier S, Seidah NG. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels[J]. J Biol Chem, 2008,283(46): 13791-13801.
[20] Seidah NG. PCSK9 as a therapeutic target of dyslipidemia[J]. Expert Opin Ther Targets, 2009,13(1):19-28.